Literature DB >> 18182586

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.

Fenghuang Zhan, Bart Barlogie, George Mulligan, John D Shaughnessy, Barb Bryant.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18182586      PMCID： PMC2200846          DOI： 10.1182/blood-2007-10-119321

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

Review 1.  Signatures of the immune response.

Authors:  A L Shaffer; A Rosenwald; E M Hurt; J M Giltnane; L T Lam; O K Pickeral; L M Staudt
Journal:  Immunity       Date:  2001-09       Impact factor: 31.745

2.  Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.

Authors:  W J Chng; W M Kuehl; P L Bergsagel; R Fonseca
Journal:  Leukemia       Date:  2007-09-06       Impact factor: 11.528

3.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

4.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

Authors:  George Mulligan; Constantine Mitsiades; Barb Bryant; Fenghuang Zhan; Wee J Chng; Steven Roels; Erik Koenig; Andrew Fergus; Yongsheng Huang; Paul Richardson; William L Trepicchio; Annemiek Broyl; Pieter Sonneveld; John D Shaughnessy; P Leif Bergsagel; David Schenkein; Dixie-Lee Esseltine; Anthony Boral; Kenneth C Anderson
Journal:  Blood       Date:  2006-12-21       Impact factor: 22.113

5.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

6.  Gene expression profiling of pediatric acute myelogenous leukemia.

Authors:  Mary E Ross; Rami Mahfouz; Mihaela Onciu; Hsi-Che Liu; Xiaodong Zhou; Guangchun Song; Sheila A Shurtleff; Stanley Pounds; Cheng Cheng; Jing Ma; Raul C Ribeiro; Jeffrey E Rubnitz; Kevin Girtman; W Kent Williams; Susana C Raimondi; Der-Cherng Liang; Lee-Yung Shih; Ching-Hon Pui; James R Downing
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

7.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; Donna S Neuberg; Jane Staunton; Mignon L Loh; Christine Huard; Susana C Raimondi; Fred G Behm; Ching Hon Pui; James R Downing; D Gary Gilliland; Eric S Lander; Todd R Golub; A Thomas Look
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743
  7 in total
  34 in total

Review 1.  The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Authors:  Sarah K Johnson; Christoph J Heuck; Anthony P Albino; Pingping Qu; Qing Zhang; Bart Barlogie; John D Shaughnessy
Journal:  Int J Hematol       Date:  2011-10-15       Impact factor: 2.490

Review 2.  A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?

Authors:  Damian J Green; William I Bensinger
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

3.  Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.

Authors:  Bijay Nair; John D Shaughnessy; Yiming Zhou; Marie Astrid-Cartron; Pingping Qu; Frits van Rhee; Elias Anaissie; Yazan Alsayed; Sarah Waheed; Klaus Hollmig; Jackie Szymonifka; Nathan Petty; Antje Hoering; Bart Barlogie
Journal:  Blood       Date:  2009-04-23       Impact factor: 22.113

Review 4.  Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.

Authors:  Matthew Ho Zhi Guang; Amanda McCann; Giada Bianchi; Li Zhang; Paul Dowling; Despina Bazou; Peter O'Gorman; Kenneth C Anderson
Journal:  Leuk Lymphoma       Date:  2017-06-13

Review 5.  Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma.

Authors:  Naimisha Marneni; Rajshekhar Chakraborty
Journal:  Curr Hematol Malig Rep       Date:  2021-04-19       Impact factor: 3.952

Review 6.  Gene Expression Profiles in Myeloma: Ready for the Real World?

Authors:  Raphael Szalat; Herve Avet-Loiseau; Nikhil C Munshi
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

7.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Authors:  Sarah K Johnson; James P Stewart; Rakesh Bam; Pingping Qu; Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

8.  Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.

Authors:  Shaji K Kumar; Hajime Uno; Susanna J Jacobus; Scott A Van Wier; Greg J Ahmann; Kimberly J Henderson; Natalie S Callander; Jessica L Haug; David S Siegel; Philip R Greipp; Rafael Fonseca; S Vincent Rajkumar
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

Review 9.  Applications of machine learning in drug discovery and development.

Authors:  Jessica Vamathevan; Dominic Clark; Paul Czodrowski; Ian Dunham; Edgardo Ferran; George Lee; Bin Li; Anant Madabhushi; Parantu Shah; Michaela Spitzer; Shanrong Zhao
Journal:  Nat Rev Drug Discov       Date:  2019-06       Impact factor: 84.694

10.  Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.

Authors:  Charles O Brown; Jeanine Schibler; Matthew P Fitzgerald; Neeraj Singh; Kelley Salem; Fenghuang Zhan; Apollina Goel
Journal:  Leuk Res       Date:  2013-03-26       Impact factor: 3.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.